Skip to main content
Premium Trial:

Request an Annual Quote

OriGene, Cytomyx Partner on Gene Expression Biomarker Validation

NEW YORK, Oct. 17 (GenomeWeb News) - OriGene Technologies and Cytomyx Holdings have signed an agreement to co-develop tools to profile gene expression and validate biomarkers in human cancers, the companies said today.


Under the terms of the agreement, Cytomyx will supply hundreds of characterized RNA samples from several major cancers. OriGene will use these samples to update its Rapid-Scan Gene Expression Panel product line, which will enable researchers to determine linkages between gene expression and tumor occurrence and development, the companies said.


Cytomyx will also develop tissue microarrays to further investigate these linkages at the protein expression level using immunohistochemistry.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.